A Blood Based Test to Predict for Response to Immune Checkpoint Inhibitors: Plasma Tumor DNA Assays for Micro-satellite Instability and Mutational Load

Case ID:
Disclosure Date:
Based on preliminary evidence, we believe that increased mutational burden occurs in patients with metastatic disease after therapy with certain chemotherapies. Based on current paradigms, this would expose a vulnerability to immune checkpoint inhibitor therapies. Thus, we propose two blood tests to determine 1) if micro-satellite instability is present after
several chemotherapy treatments and 2) if increased mutational burden could be detected as a predictive marker for sensitivity to immune checkpoint therapies. These tests could allow for selecting only those patients with the highest likelihood of responding to immune checkpoint inhibitor therapies.
Patent Information:
For Information, Contact:
Christine Joseph
Save This Technology:
2017 © Johns Hopkins Technology Ventures. All Rights Reserved. Powered by Inteum